|
| Median age (range), years |
54 (18–73) |
54 (18–72) |
|
| Male, n (%) |
230 (55) |
150 (54) |
|
| Disease, n (%) |
|
|
| AML |
252 (61) |
164 (59) |
| ALL |
57 (14) |
33 (12) |
| MDS |
107 (26) |
79 (29) |
|
| KPS, n (%) |
|
|
| 90–100 |
222 (53) |
160 (58) |
| 80 |
147 (35) |
94 (34) |
| <80 |
27 (6) |
14 (5) |
| Data not available |
20 (5) |
8 (3) |
|
| HCT-CI, n (%) |
|
|
| 0 |
88 (21) |
72 (26) |
| 1–2 |
130 (31) |
90 (33) |
| ≥ 3 (range, 3–10) |
198 (48) |
114 (41) |
|
| Conditioning regimen, n (%) |
|
|
| TBI/thiotepa/fludarabine |
85 (20) |
53 (19) |
| TBI/thiotepa/cyclophosphamide |
79 (19) |
53(19) |
| Busulfan/melphalan/fludarabine |
241 (58) |
163 (59) |
| Clofarabine/melphalan/thiotepa |
11 (3) |
8 (3) |
|
| Donor type, n (%) |
|
|
| 8/8-matched related |
155 (37) |
108 (39) |
| 8/8-matched unrelated |
159 (38) |
101 (37) |
| Mismatched related |
11 (3) |
8 (3) |
| 7/8-matched, n |
9 |
6 |
| 6/8-matched, n |
2 |
2 |
| Mismatched unrelated |
91 (22) |
59 (21) |
| 7/8-matched, n |
85 |
55 |
| 6/8-matched, n |
6 |
4 |
|
| CD34 selection method, n (%) |
|
|
| ISOLEX 300i and sRBC |
241 (58) |
158 (57) |
| CliniMACS |
175 (42) |
118 (43) |
|
| Antithymocyte globulin (ATG), n (%) |
|
|
| Any ATG |
376 (90) |
248 (90) |
| Rabbit ATG (2.5-10 mg/kg) |
301 (72) |
202 (73) |
| Equine ATG (30–45 mg/kg) |
73 (18) |
46 (17) |
| Rabbit and equine ATG |
2 (<1) |
0 (0) |
|
| AML |
n=251 |
n=164 |
|
| Disease status at HSCT, n (%) |
|
|
| CR1 |
171 (68) |
116 (71) |
| CR2 or greater |
68 (27) |
40 (24) |
| PR |
9 (4) |
6 (4) |
| Refractory |
3 (1) |
2 (1) |
|
| Risk group, n (%) |
|
|
| Favorable |
20 (8) |
18 (11) |
| Intermediate |
139 (55) |
95 (58) |
| Poor |
91 (36) |
51 (31) |
| Unknown |
1 (<1) |
0 |
|
| Therapy-related AML, n (%) |
34 (14) |
22 (13) |
|
| FLT3-ITD or -TKD, n (%) |
|
|
| Positive |
26 (10) |
19 (12) |
| Negative |
67 (27) |
43 (26) |
| Data not available |
157 (63) |
102 (62) |
|
| Isolated NPM1 mutation, n (%) |
|
|
| Yes |
5 (2) |
4 (2) |
| No |
63 (25) |
42 (26) |
| Data not available |
183 (73) |
118 (72) |
|
| ALL |
n=57 |
n=33 |
|
| Disease status at HSCT, n (%) |
|
|
| CR1 |
43 (75) |
27 (82) |
| CR2 or greater |
13 (23) |
5 (15) |
| Refractory |
1 (2) |
1 (3) |
|
| Cytogenetic risk, n (%) |
|
|
| Standard/good |
23 (40) |
13 (39) |
| Poor |
34 (60) |
20 (61) |
|
| Phenotype, n (%) |
|
|
| B-cell |
46 (81) |
27 (82) |
| BCR-ABL1+ |
28 (49) |
18 (55) |
| T-cell |
9 (16) |
5 (15) |
| B/T-cell or NK |
2 (4) |
1 (3) |
|
| MDS |
n=108 |
n=79 |
|
| Disease status at HSCT, n (%) |
|
|
| CR |
22 (20) |
14 (18) |
| Non-CR |
86 (80) |
65 (82) |
| <5% blasts |
69 (64) |
53 (67) |
| 5–10% blasts |
14 (13) |
9 (11) |
| Unknown |
3 (3) |
3 (4) |
|
| Therapy received pre-HSCT, n (%) |
91 (84) |
67 (85) |
|
| IPSS-R at diagnosis, n (%) |
|
|
| Very low |
5 (5) |
3 (4) |
| Low |
21 (19) |
15 (19) |
| Intermediate |
31 (29) |
28 (35) |
| High |
19 (18) |
15 (19) |
| Very high |
21 (19) |
12 (15) |
| Data not available |
11 (10) |
6 (8) |
|
| IPSS-R at HSCT, n (%) |
|
|
|
| Very low |
5 (5) |
4 (5) |
| Low |
36 (33) |
30 (38) |
| Intermediate |
38 (35) |
25 (32) |
| High |
17 (16) |
11 (14) |
| Very high |
9 (8) |
6 (8) |
| Data not available |
3 (3) |
3 (4) |
|
| Therapy-related MDS, n (%) |
24 (22) |
13 (16) |
